Physician profile
Brett D Kalmowitz
NPI 1700817269
$4,249.18
in general payments reported to CMS, 2019-2025
22 companies · $2,252 in 2025
The $2,252 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $826 · 2020: $297 · 2021: $28.06 · 2022: $280 · 2023: $190 · 2024: $376 · 2025: $2,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,655 · Consulting Fee: $1,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,655.49 |
| Consulting Fee | $1,162.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,162.50 | 2025 | Imfinzi |
| Abbvie INC. | $767.21 | 2019-2025 | |
| Janssen Biotech, INC. | $526.44 | 2019-2025 | Tremfya |
| Medtronic, INC. | $244.20 | 2022-2023 | Barrx |
| Phathom Pharmaceuticals, INC. | $235.27 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $144.23 | 2025 | Rezdiffra |
| Allergan, INC. | $143.61 | 2019-2020 | |
| Novo Nordisk INC | $138.71 | 2025 | Wegovy |
| Pfizer INC. | $135.36 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $132.59 | 2019-2020 | |
| Lilly USA, LLC | $110.19 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.10 | 2019-2024 | Eohilia |
| Boston Scientific Corporation | $89.67 | 2022 | |
| Nestle Healthcare Nutrition INC. | $77.04 | 2023 | |
| Ucb, INC. | $72.24 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $32.93 | 2019-2020 | |
| Shionogi INC | $32.86 | 2019 | |
| Ironwood Pharmaceuticals, INC | $32.78 | 2019-2020 | |
| Braintree Laboratories, INC. | $25.26 | 2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $18.85 | 2019 | |
| Gilead Sciences, INC. | $17.89 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Kalmowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.